Recent News

• 09.12.2025 - Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 09.04.2025 - Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
• 09.03.2025 - Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 09.02.2025 - Opus Genetics Appoints Rob Gagnon as Chief Financial Officer
• 08.27.2025 - Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September
• 08.18.2025 - Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
• 08.13.2025 - Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

Recent Filings

• 09.11.2025 - 3 Initial statement of beneficial ownership of securities
• 09.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.10.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 09.02.2025 - EX-99.1 EX-99.1
• 09.02.2025 - 8-K Current report
• 08.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.25.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - EX-99.1 EX-99.1